CARDIOVASCULAR
hamburger
product photo

SMOOTH. AGILE.

  • Smooth Tracking Through Challenging Anatomy
    • Delivery system to enhance acute performance of the proven XIENCE implant
  • XIENCE Safety
    • Consistently Low Stent Thrombosis Rates. Trial after Trial.1,2

 

1. Bangalore S, et al. BMJ, Nov 2013. 347:f6625 doi: 10.1136/bmj.f6625.
2. Palmerini T et al. JACC Nov 2013 doi: 10.1016/j.jacc.2013.09.061.

SMOOTH TRACKING THROUGH CHALLENGING ANATOMY

STENT DELIVERY SYSTEM DRIVES ACUTE PERFORMANCE
  • Catheter performance test results show 22% less force is used to deliver XIENCE Xpedition versus XIENCE PRIME1
PROVEN XIENCE IMPLANT
  • Efficacious low dose of everolimus2
  • Biocompatible coating technology
  • Over 20 million MULTI-LINK stents implanted to date worldwide3

xience-xpedition-trackable-in%</p>

 

Trackable1

Track smoothly around sharp bends in tortuous anatomy

Fully integrated tip continues to guide wire notch with no transitions for excellent tracking

Ultra low distal seal technology for outstanding crossability

xience-xpedition-flexible-int

Flexible1

Deliver with confidence

Flexible multi-layered balloon with flatter compliance

xience-xpedition-pushable-int

Pushable1

Cross challenging anatomy with ease

Hypotube skive transition for exceptional support

Smooth and reduced transitions across the entire system for optimal force transfer


1. Test(s) performed by and data on file at Abbott.
2. Kedhi E, et al. Lancet, Jan 2010. 375:201-09
3. Includes MULTI-LINK, MULTI-LINK DUET, MULTI-LINK TRISTAR, MULTI-LINK TETRA, MULTI-LINK PENTA, MULTI-LINK ZETA, MULTI-LINK MINI VISION, MULTI-LINK VISION, MULTI-LINKPIXEL, MULTI-LINK ULTRA, MULTI-LINK 8, XIENCE PRIME, XIENCE V, PROMUS, XIENCE PRO, XIENCE Xpedition and XIENCE PRO X, XIENCE ALPINE, XIENCE PRO A and XIENCE SIERRA. Based on sales data through Q4 2018 and data on file at Abbott.

XIENCE SAFETY

xience


1. BMS is a composite of several bare metal stents as a representation of the BMS category.
2. An odds ratio is a method of comparing the odds of an event between two groups.
3. A rate ratio was calculated instead of an odds ratio.
4. Median follow-up was 1.9 years in this study.
5. Median follow-up was 2.2 years in this study.
6. Palmerini T, et al. The Lancet. March 23, 2012; 379:1393-1402.
7. Bangalore S, et al. Circulation May 14, 2012;125:2873-2891.
8. Bangalore S, et al. British Medical Journal, Aug 10, 2012. 345:e5170 doi: 10.1136/bmj.e5170.
9. Palmerini T, et al. JACC. June 7, 2013;62:496-504.
10. Bangalore S, et al. Circ Cardiovasc Interv, Aug 6, 2013. doi: 10.1161/ circinterventions. 113.000415.


xience


Valgimigli, M, Effects of Cobalt-chromium everolimus eluting or bare metal stent on fatal and non-fatal cardiovascular events. A patient-level meta analysis. EuroPCR 2014.
*BMS is a composite of several bare metal stents as a representation of the BMS category


xience


1. Bangalore S, et al. BMJ, Nov 2013. 347:f6625 doi: 10.1136/bmj.f6625.
2. Palmerini T et al. JACC Nov 2013 doi: 10.1016/j.jacc.2013.09.061.
3. An odds ratio is a method of comparing the incidence of events between two groups.
4. A rate ratio was calculated instead of an odds ratio.

"Meta-analyses should be regarded as hypothesis-generating and the findings of Palmerini and colleagues suggest that a randomized trial of CoCr EES and BMS is desirable." Ormiston, The Lancet, April 2012
The XIENCE system’s clinical outcomes result from its components, including: a thin-strut, flexible ring and link design, with favorable strut apposition, no metal-to-metal touch points, and low strain upon expansion; the novel Everolimus compound; and the multi-layer coating and primer technologies, using a fluorinated polymer class known for cardiovascular implants, and known for having excellent mechanical properties.
Note: The above charts are illustrative representation of various odds ratios from the sourced meta-analyses.
Note: XIENCE has demonstrated reduced event rates in the safety endpoints of stent thrombosis, death and MI versus several BMS and BP-DES in multiple large scale meta-analyses. Sources: Dr. Valgimigli, EuroPCR 2014; Palmerini et al. Lancet. 2012;379:1393-402; Bangalore et al. Circulation 2012;125:2873-2891

Stent Diameter Stent Length
8 mm 12 mm 15 mm 18 mm 23 mm
2.00 mm 1070200-08 1070200-12 1070200-15 1070200-18 1070200-23
2.25 mm 1070225-08 1070225-12 1070225-15 1070225-18 1070225-23
2.50 mm 1070250-08 1070250-12 1070250-15 1070250-18 1070250-23
2.75 mm 1070275-08 1070275-12 1070275-15 1070275-18 1070275-23
3.00 mm 1070300-08 1070300-12 1070300-15 1070300-18 1070300-23
3.25 mm 1070325-08 1070325-12 1070325-15 1070325-18 1070325-23
3.50 mm 1070350-08 1070350-12 1070350-15 1070350-18 1070350-23
4.00 mm 1070400-08 1070400-12 1070400-15 1070400-18 1070400-23


Stent Diameter Stent Length
28 mm 33 mm 38 mm 48 mm
2.00 mm 1070200-28 - - -
2.25 mm 1070225-28 - - -
2.50 mm 1070250-28 1070250-33 1070250-38 1070250-48
2.75 mm 1070275-28 1070275-33 1070275-38 1070275-48
3.00 mm 1070300-28 1070300-33 1070300-38 1070300-48
3.25 mm 1070325-28 1070325-33 1070325-38 -
3.50 mm 1070350-28 1070350-33 1070350-38 1070350-48
4.00 mm 1070400-28 1070400-33 1070400-38 -

X

AP2946435-WBO Rev. A

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?

true
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?